The global drug testing market size was estimated at USD 7.09 billion in 2025 and is projected to reach USD 11.55 billion by 2033, growing at a CAGR of 6.32% from 2026 to 2033. The rising prevalence of substance abuse worldwide has increased the demand for testing solutions.
In addition, strict regulations from various government bodies requiring alcohol and substance testing for safety reasons, along with increased initiatives to monitor and address substance abuse, are anticipated to further enhance market growth.
The rising global rates of substance abuse have considerably increased the demand for testing solutions. According to the Substance Abuse and Mental Health Services Administration (SAMHSA) 2024 National Survey on Drug Use and Health, about 73.6 million Americans aged 12 or older (25.5%) reported using illicit drugs in the past year. Cannabis remains the most commonly used illicit drug, with around 64.2 million users, followed by substances such as hallucinogens, prescription opioids, and cocaine. The ongoing opioid crisis has also increased the need for monitoring and testing programs across healthcare, workplace, and law enforcement sectors. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded over 107,000 drug overdose deaths in 2023, highlighting the serious public health impact of drug misuse. These rising cases of substance misuse and overdose are encouraging governments, employers, and healthcare providers to adopt regular drug screening and monitoring programs, which is supporting the growth of the U.S. drug testing industry.
Moreover, the alarming rise in alcohol and substance-related deaths emphasizes the urgent need for reliable testing solutions, driving demand for innovative technologies and services to support substance abuse detection, treatment, and prevention efforts in healthcare and public safety sectors. In June 2024, WHO report shows that over 3 million annual deaths are linked to alcohol and substance use, predominantly affecting men. Of these, 2.6 million deaths are due to alcohol, while 0.6 million are attributed to psychoactive drugs. The report highlights that around 400 million people suffer from alcohol use disorders globally, with 209 million experiencing dependence. Despite some declines in alcohol-related death rates, the overall figures remain alarmingly high, especially in low-income countries. The report calls for urgent actions to reduce alcohol and drug consumption and improve access to treatment, emphasizing the need for a coordinated global advocacy campaign and enhanced treatment capabilities in healthcare systems to achieve Sustainable Development Goal 3.5 by 2033.
Increased resources for treatment programs may lead to a higher demand for testing services to monitor compliance and effectiveness of treatments. The emphasis on addressing substance use disorders, especially among underserved populations, can spur innovations in technologies and methodologies. Furthermore, with comprehensive opioid recovery initiatives, there may be a greater need for accurate screening to prevent misuse, ultimately supporting growth in the market. In July 2024, The Biden-Harris Administration has awarded USD 45.1 million to expand services for substance use disorders. Key initiatives include USD 7.5 million for homeless individuals with substance use disorders, USD 4 million for minorities at high risk for HIV/AIDS, and USD 1.7 million for comprehensive opioid recovery centers.
In addition, strict regulations from various government bodies requiring alcohol and substance testing for safety reasons, along with increased initiatives to monitor and address substance abuse, are anticipated to further enhance market growth.
The rising global rates of substance abuse have considerably increased the demand for testing solutions. According to the Substance Abuse and Mental Health Services Administration (SAMHSA) 2024 National Survey on Drug Use and Health, about 73.6 million Americans aged 12 or older (25.5%) reported using illicit drugs in the past year. Cannabis remains the most commonly used illicit drug, with around 64.2 million users, followed by substances such as hallucinogens, prescription opioids, and cocaine. The ongoing opioid crisis has also increased the need for monitoring and testing programs across healthcare, workplace, and law enforcement sectors. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded over 107,000 drug overdose deaths in 2023, highlighting the serious public health impact of drug misuse. These rising cases of substance misuse and overdose are encouraging governments, employers, and healthcare providers to adopt regular drug screening and monitoring programs, which is supporting the growth of the U.S. drug testing industry.
Moreover, the alarming rise in alcohol and substance-related deaths emphasizes the urgent need for reliable testing solutions, driving demand for innovative technologies and services to support substance abuse detection, treatment, and prevention efforts in healthcare and public safety sectors. In June 2024, WHO report shows that over 3 million annual deaths are linked to alcohol and substance use, predominantly affecting men. Of these, 2.6 million deaths are due to alcohol, while 0.6 million are attributed to psychoactive drugs. The report highlights that around 400 million people suffer from alcohol use disorders globally, with 209 million experiencing dependence. Despite some declines in alcohol-related death rates, the overall figures remain alarmingly high, especially in low-income countries. The report calls for urgent actions to reduce alcohol and drug consumption and improve access to treatment, emphasizing the need for a coordinated global advocacy campaign and enhanced treatment capabilities in healthcare systems to achieve Sustainable Development Goal 3.5 by 2033.
Increased resources for treatment programs may lead to a higher demand for testing services to monitor compliance and effectiveness of treatments. The emphasis on addressing substance use disorders, especially among underserved populations, can spur innovations in technologies and methodologies. Furthermore, with comprehensive opioid recovery initiatives, there may be a greater need for accurate screening to prevent misuse, ultimately supporting growth in the market. In July 2024, The Biden-Harris Administration has awarded USD 45.1 million to expand services for substance use disorders. Key initiatives include USD 7.5 million for homeless individuals with substance use disorders, USD 4 million for minorities at high risk for HIV/AIDS, and USD 1.7 million for comprehensive opioid recovery centers.
Global Drug Testing Market Report Segmentation
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global drug testing market report based on product, sample, drug, end-use, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Consumables
- Instruments
- Rapid Testing Devices
- Services
Sample Outlook (Revenue, USD Million, 2021-2033)
- Urine Samples
- Oral Fluid Samples
- Hair Samples
- Other Samples
Drug Outlook (Revenue, USD Million, 2021-2033)
- Alcohol
- Cannabis/Marijuana
- Cocaine
- Opioids
- Amphetamine & Methamphetamine
- LSD
- Others
End-use Outlook (Revenue, USD Million, 2021-2033)
- Drug Testing Laboratories
- Workplaces
- Hospitals
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Drug Testing Market Variables, Trends & Scope
Chapter 4. Drug Testing Market: Product Estimates & Trend Analysis
Chapter 5. Drug Testing Market: Sample Estimates & Trend Analysis
Chapter 6. Drug Testing Market: Drug Estimates & Trend Analysis
Chapter 7. Drug Testing Market: End use Estimates & Trend Analysis
Chapter 8. Drug Testing Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Quest Diagnostics Incorporated
- Abbott
- F. Hoffmann-La Roche Ltd.
- Quidel Corporation
- Thermo Fisher Scientific, Inc.
- Siemens Healthcare GmbH
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- Laboratory Corporation of America Holdings
- Clinical Reference Laboratory, Inc.
- Cordant Health Solutions
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 7.09 Billion |
| Forecasted Market Value ( USD | $ 11.55 Billion |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
